Citi analyst Yigal Nochomovitz reiterated a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report) yesterday and set a price target of $8.00. The company’s shares closed yesterday at $2.60.

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...